Dr. David Perlmutter

speaker

585 appearances 1 recordings 1 series first heard Jul 2026 last heard 15 Jul

Dr. David Perlmutter’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

Be Well by Kelly Leveque · 393: Alzheimer's Starts Decades Before Symptoms…Here's Why | David Perlmutter · 15 Jul 2026 podcast

So I think we're going to see that soon.

But that said, if GLP-1s prove to be effective in this situation, which is a metabolic issue that you and I have been talking about all day,

then I'm in.

You bet I'm in.

We've got to look at risk-benefit ratio.

We've got to look at above all, do no harm.

We don't want to hurt people by giving these drugs.

But again, this is a fatal condition.

And if taking this drug, I think that people who are using

Ozempic or other GLP-1s for weight loss realize that they're pretty much committing, at least the macrodose people, they're committing to being on this drug forever because when they stop, they get rebound and that can be threatening, obviously.

I think the idea in a fatal condition of using a GLP-1, I'm going to be open to it.

As it relates to microdosing, I think we've not seen any data yet.

I think it's fascinating.

I think microdosing more than just with GLP-1s may have a significant play as it relates to the brain.

What I said just now is, yes, I do discuss psilocybin in the book.

because there is some fascinating research looking at psilocybin that may actually prove positive, keeping very much an open mind.

And we actually, at the very last chapter of that book, talk about what is on both the near and the far horizon in terms of research and development as it relates to ways of targeting our microglia

beyond what we could do today.

What are the technology approaches?

What are the pharmaceutical approaches?

Showing 481–500 of 585 · page 25 of 30